Browse All

Current Filters

CLEAR FILTER x

TITLE

Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials

Author:Filippi, Massimo   Riolo, Jon   Cohen, Jeffrey   Hartung, Hans-Peter   Montalban, Xavier   Meuth, Sven   Freeman, Leorah   Chitnis, Tanuja   Granziera, Cristina   Deboer, Erik   Cheng, Chun-Yen   Reardon, Jennifer   Pachai, Chahin   Sheffield, James   Cree, Bruce   Kappos, Ludwig   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.014  

Author Institution:Neuroimaging Research Unit, Division of Neuroscience, Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy, Milan, Italy  Bristol Myers Squibb, Princeton, New Jersey, USA, Princeton, NJ  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Sydney, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, Duesseldorf, Germany  Dell Medical School, The University of Texas at Austin, Austin, Texas, USA, Austin, TX  Brigham and Women’s Hospital, and Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, Boston, MA  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland  Department of Neurology, University Hospital Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Bristol Myers Squibb, Princeton, New Jersey, USA, New York, NY  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA , San Francisco, CA  

Eight-point Reliable Change on Symbol Digit Modalities Test with Ozanimod: Findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials